公司資料
Unicycive Therapeutics 股價、新聞與催化劑
- 股票代碼:
- UNCY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.57 USD (+1.09%)
收盤價
最後更新: 2026年8月17日
193M USD
市值
股價為何變動
As of Aug 17, 2026, UNCY closed up 1.09% at $5.57. No new same-company headline was identified in the current news window.
公司概覽
Kidney Disease Therapeutics
Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Oxylanthanum Carbonate
Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies.
Regulatory Resubmission Path
The FDA's prior review did not identify efficacy or safety deficiencies but required resolution of manufacturing-facility issues. A third-party vendor inspection is the key step preceding NDA resubmission.
未來催化劑
- Completion of the FDA inspection of the third-party oxylanthanum carbonate manufacturing facility.
- Resubmission of the oxylanthanum carbonate NDA following a successful facility inspection.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。